uniQure (NASDAQ:QURE) Given New $80.00 Price Target at HC Wainwright

uniQure (NASDAQ:QURE) had its target price boosted by equities researchers at HC Wainwright from $50.00 to $80.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 68.39% from the stock’s current price.

QURE has been the subject of a number of other reports. Barclays upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $25.00 to $65.00 in a report on Thursday, June 18th. Leerink Partners boosted their price target on uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Cantor Fitzgerald upgraded uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target for the company in a research note on Wednesday, June 17th. TD Cowen reissued a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Finally, Stifel Nicolaus set a $28.00 price objective on uniQure in a research note on Tuesday, May 5th. Twelve research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $64.17.

uniQure Price Performance

QURE opened at $47.51 on Monday. The stock has a market capitalization of $3.00 billion, a PE ratio of -13.65 and a beta of 0.98. The company’s 50 day simple moving average is $27.84 and its 200 day simple moving average is $23.03. uniQure has a 1 year low of $8.73 and a 1 year high of $71.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. As a group, sell-side analysts expect that uniQure will post -3.65 EPS for the current year.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 164,429 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $44.32, for a total value of $7,287,493.28. Following the sale, the chief executive officer directly owned 558,810 shares of the company’s stock, valued at approximately $24,766,459.20. This trade represents a 22.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Gut sold 7,552 shares of uniQure stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $26.05, for a total value of $196,729.60. Following the completion of the transaction, the director owned 27,435 shares in the company, valued at $714,681.75. The trade was a 21.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 359,546 shares of company stock worth $14,549,943. Corporate insiders own 4.65% of the company’s stock.

Institutional Trading of uniQure

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in uniQure by 15.7% during the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock worth $65,673,000 after acquiring an additional 152,417 shares during the period. Aberdeen Group plc boosted its holdings in uniQure by 25.1% in the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after purchasing an additional 738,897 shares during the period. Quinn Opportunity Partners LLC acquired a new stake in uniQure in the 3rd quarter worth $6,281,000. Farallon Capital Management LLC increased its holdings in shares of uniQure by 3,935.7% during the 3rd quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock worth $32,979,000 after purchasing an additional 551,000 shares during the period. Finally, Boone Capital Management LLC bought a new position in shares of uniQure during the 3rd quarter worth about $8,599,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.